AstraZeneca awarded damages in Prilosec® patent litigation

AstraZeneca's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Tuesday, 3 December 2013

AstraZeneca today announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc. (“Apotex”) to pay AstraZeneca approximately $76 million in damages. This ruling is a result of Apotex’s infringing sales of generic omeprazole between 2004 and 2007. This follows a previous ruling in 2007 that found two Prilosec® (omeprazole) formulation patents valid and infringed by Apotex.

AstraZeneca welcomes the court’s ruling.

These damages will not impact Core earnings or AstraZeneca’s full year 2013 financial guidance.

NOTES TO EDITORS

About the litigation

In June of 2007, Judge Barbara S. Jones of the United States District Court for the Southern District of New York upheld two of AstraZeneca’s formulation patents covering Prilosec®, a ruling consistent with her earlier decision related to the same patents in October 2002. The Court found that Apotex’s generic omeprazole formulation infringed both patents in suit.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

News Source : AstraZeneca awarded damages in Prilosec® patent litigation

Copy this html code to your website/blog to embed this press release.